Quarterly Report • Jul 16, 2020
Quarterly Report
Open in ViewerOpens in native device viewer
| Income Statement Borregaard Group Q2 2020 | |||||
|---|---|---|---|---|---|
| 1.4-30.6 | 1.1-30.6 | 1.1-31.12 | |||
| Amounts in NOK million | 2020 | 2019 | 2020 | 2019 | 2019 |
| Operating revenues | 1 358 | 1 340 | 2 730 | 2 590 | 5 063 |
| Operating expenses | -997 | -1 057 | -2 127 | -2 052 | -4 056 |
| EBITDA | 361 | 283 | 603 | 538 | 1 007 |
| Depreciation property, plant and equipment | -112 | -104 | -221 | -202 | -418 |
| Amortisation intangible assets | -1 | -1 | -2 | -2 | -4 |
| Other income and expenses | -96 | -16 | -96 | -16 | -27 |
| Operating profit | 152 | 162 | 284 | 318 | 558 |
| Financial items, net | -19 | -22 | -40 | -37 | -91 |
| Profit before taxes | 133 | 140 | 244 | 281 | 467 |
| Income tax expence | -48 | -33 | -75 | -66 | -116 |
| Profit for the period | 85 | 107 | 169 | 215 | 351 |
| Profit attributable to non-controlling interests | -16 | -15 | -34 | -33 | -66 |
| Profit attributable to owners of the parent | 101 | 122 | 203 | 248 | 417 |
| Earnings per share (NOK) | 1,01 | 1,22 | 2,03 | 2,48 | 4,17 |
| EBITDA adj. margin | 26,6 % | 21,1 % | 22,1 % | 20,8 % | 19,9 % |
| Interim condensed statement of financial position Borregaard Group | |||
|---|---|---|---|
| 30.6. | 31.3. | 31.12. | |
| Amounts in NOK million | 2020 | 2020 | 2019 |
| Assets: | |||
| Intangible assets | 94 | 98 | 93 |
| Property, plant and equipment | 3 975 | 3 984 | 3 852 |
| Right-of-use assets | 374 | 396 | 380 |
| Other assets | 284 | 398 | 251 |
| Investments in joint venture | 26 | 94 | 99 |
| Non-current assets | 4 753 | 4 970 | 4 675 |
| Inventories | 1 003 | 942 | 931 |
| Receivables | 1 120 | 1 368 | 991 |
| Cash and cash deposits | 67 | 61 | 147 |
| Current assets | 2 190 | 2 371 | 2 069 |
| Total assets | 6 943 | 7 341 | 6 744 |
| Equity and debt: | |||
| Group equity | 2 926 | 2 641 | 3 306 |
| Non-controlling interests | 141 | 169 | 158 |
| Equity | 3 067 | 2 810 | 3 464 |
| Provisions and other liabilities | 444 | 813 | 294 |
| Interest-bearing liabilities | 1 530 | 1 820 | 1 419 |
| Non-current liabilities | 1 974 | 2 633 | 1 713 |
| Interest-bearing liabilities | 694 | 617 | 608 |
| Other current liabilities | 1 208 | 1 281 | 959 |
| Current liabilities | 1 902 | 1 898 | 1 567 |
| Equity and liabilities | 6 943 | 7 341 | 6 744 |
| Equity ratio (%): | 44,2 % | 38,3 % | 51,4 % |
| Interim condensed cash flow statement Borregaard Group Q2 2020 | |||||||
|---|---|---|---|---|---|---|---|
| 1.4-30.6 | 1.1-30.6 | 1.1-31.12 | |||||
| Amounts in NOK million | 2020 | 2019 | 2020 | 2019 | 2019 | ||
| Profit before taxes | 133 | 140 | 244 | 281 | 467 | ||
| Amortisation, depreciation and impairment charges | 113 | 105 | 223 | 204 | 432 | ||
| Change in net working capital, etc | 134 | -91 | -164 | -219 | -85 | ||
| Dividend (share of profit) from JV | 64 | 0 | 63 | 0 | 5 | ||
| Taxes paid | -2 | -21 | -49 | -89 | -122 | ||
| Cash flow from operating activities | 442 | 133 | 317 | 177 | 697 | ||
| Investments property, plant and equipment and intangible assets * | -155 | -146 | -213 | -269 | -583 | ||
| Other capital transactions | 3 | 2 | 5 | 11 | 29 | ||
| Cash flow from Investing activities | -152 | -144 | -208 | -258 | -554 | ||
| Dividends | -229 | -224 | -229 | -224 | -224 | ||
| Proceeds from exercise of options/shares to employees | 1 | 11 | 29 | 30 | 35 | ||
| Buy-back of shares | 0 | -21 | -50 | -48 | -60 | ||
| Gain/(loss) on hedges for net investments in subsidiaries | 113 | 5 | -47 | 9 | -26 | ||
| Net paid to/from shareholders | -115 | -229 | -297 | -233 | -275 | ||
| Proceeds from interest-bearing liabilities | 300 | 1 000 | 950 | 1 347 | 2 100 | ||
| Repayment of interest-bearing liabilities | -345 | -837 | -930 | -1 053 | -1 971 | ||
| Change in interest-bearing receivables/other liabilities | -14 | 1 | 26 | -7 | -3 | ||
| Change in net interest-bearing liablities | -59 | 164 | 46 | 287 | 126 | ||
| Cash flow from financing activities | -174 | -65 | -251 | 54 | -149 | ||
| Change in cash and cash equivalents | 116 | -76 | -142 | -27 | -6 | ||
| Cash and cash equivalents at beginning of period | -171 | 134 | 81 | 86 | 86 | ||
| Change in cash and cash equivalents | 116 | -76 | -142 | -27 | -6 | ||
| Currency effects cash and cash equivalents | -4 | 1 | 2 | 0 | 1 | ||
| Cash and cash equivalents at the end of the period | -59 | 59 | -59 | 59 | 81 | ||
| * Investment by category: | |||||||
| Replacement investments | 104 | 54 | 139 | 130 | 370 | ||
| Expansion investments | 51 | 92 | 74 | 139 | 213 |
| Operating revenues | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.1-30.6 | |
| Amounts in NOK million | 2016 | 2017 | 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
| Borregaard | 4 492 | 4 618 | 1 217 | 1 199 | 1 150 | 1 219 | 4 785 | 1 250 | 1 340 | 1 239 | 1 234 | 5 063 | 1 372 | 1 358 | 2 730 |
| BioSolutions | 2 563 | 2 594 | 687 | 693 | 690 | 705 | 2 775 | 755 | 781 | 720 | 726 | 2 982 | 797 | 819 | 1 616 |
| BioMaterials | 1 575 | 1 672 | 432 | 426 | 378 | 425 | 1 661 | 394 | 472 | 430 | 416 | 1 712 | 454 | 417 | 871 |
| Fine Chemicals | 368 | 370 | 103 | 86 | 89 | 96 | 374 | 110 | 96 | 96 | 104 | 406 | 128 | 131 | 259 |
| Eliminations | - 14 | - 18 | - 5 | - 6 | - 7 | - 7 | - 25 | -9 | -9 | -7 | -12 | -37 | -7 | -9 | -16 |
| EBITDA | |||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.1-30.6 | |
| Amounts in NOK million | 2016 | 2017 | 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
| Borregaard | 1 021 | 1 055 | 252 | 239 | 229 | 183 | 903 | 255 | 283 | 286 | 183 | 1 007 | 242 | 361 | 603 |
| BioSolutions | 605 | 545 | 149 | 139 | 112 | 99 | 499 | 168 | 192 | 156 | 131 | 647 | 170 | 193 | 363 |
| BioMaterials | 321 | 414 | 74 | 79 | 95 | 64 | 312 | 45 | 64 | 94 | 31 | 234 | 46 | 101 | 147 |
| Fine Chemicals | 95 | 96 | 29 | 21 | 22 | 20 | 92 | 42 | 27 | 36 | 21 | 126 | 26 | 67 | 93 |
| Depreciations and write downs | |||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.1-30.6 | |
| Amounts in NOK million | 2016 | 2017 | 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
| Borregaard | - 274 | - 306 | - 75 | - 75 | - 84 | - 89 | - 323 | -98 | -104 | -106 | -110 | -418 | -109 | -112 | -221 |
| BioSolutions | - 78 | - 94 | - 24 | - 23 | - 32 | - 34 | - 113 | -41 | -44 | -48 | -50 | -183 | -51 | -51 | -102 |
| BioMaterials | - 177 | - 192 | - 46 | - 47 | - 47 | - 49 | - 189 | -49 | -53 | -50 | -51 | -203 | -50 | -52 | -102 |
| Fine Chemicals | - 19 | - 20 | - 5 | - 5 | - 5 | - 6 | - 21 | -8 | -7 | -8 | -9 | -32 | -8 | -9 | -17 |
| Amortisation | |||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.1-30.6 | |
| Amounts in NOK million | 2016 | 2017 | 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
| Borregaard | - 4 | - 4 | - 1 | - 1 | - 1 | - 1 | - 4 | -1 | -1 | -1 | -1 | -4 | -1 | -1 | -2 |
| BioSolutions | - 4 | - 4 | - 1 | - 1 | - 1 | - 1 | - 4 | -1 | -1 | -1 | -1 | -4 | -1 | -1 | -2 |
| BioMaterials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income and expenses | |||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.1-30.6 | |
| Amounts in NOK million | 2016 | 2017 | 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
| Borregaard | 13 | -9 | 0 | 0 | 0 | 0 | 0 | 0 | -16 | 0 | -11 | -27 | 0 | -96 | -96 |
| BioSolutions | -24 | -9 | 0 | 0 | 0 | 0 | 0 | 0 | -16 | 0 | 0 | -16 | 0 | -90 | |
| -90 | |||||||||||||||
| BioMaterials | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11 | -11 | 0 | -6 | -6 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit (EBIT) | |||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.1-30.6 | |
| Amounts in NOK million | 2016 | 2017 | 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
| Borregaard | 756 | 736 | 176 124 |
163 | 144 | 93 | 576 | 156 | 162 | 179 | 61 | 558 444 |
132 | 152 51 |
284 |
| BioSolutions | 499 | 438 | 169 | ||||||||||||
| 115 | 79 | 64 | 382 | 126 | 131 | 107 | 80 | 118 | |||||||
| BioMaterials Fine Chemicals |
181 76 |
222 76 |
28 24 |
32 16 |
48 17 |
15 14 |
123 71 |
-4 34 |
11 20 |
44 28 |
-31 12 |
20 94 |
-4 18 |
43 58 |
39 76 |
| Hedging effects & currency exposure 1.1-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 |
1.1-30.6 |
|---|---|
| Amounts in NOK million 2016 2017 2018 2018 2018 2018 2018 2019 2019 2019 2019 2019 2020 2020 |
2020 |
| Borregaard - EBITDA hedging gains & losses -115 -72 3 -6 -7 -1 -11 -8 -13 -23 -32 -76 -62 -84 |
-146 |
| BioSolutions -41 -22 3 1 0 -1 3 -4 -6 -9 -14 -33 -26 -38 |
-64 |
| BioMaterials -59 -36 2 -2 -2 -1 -3 -3 -7 -11 -16 -37 -30 -39 |
-69 |
| Fine Chemicals -15 -14 -2 -5 -5 1 -11 -1 0 -3 -2 -6 -6 -7 |
-13 |
| Borregaard - USD EBITDA currency exposure (approx) 209 207 194 203 |
|
| Borregaard - EUR EBITDA currency exposure (approx) 92 84 84 98 |
|
| Sales revenues | |
| 1.1-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 |
1.1-30.6 |
| Amounts in NOK million 2016 2017 2018 2018 2018 2018 2018 2019 2019 2019 2019 2019 2020 2020 |
2020 |
| Borregaard 4 391 4 522 1 195 1 179 1 131 1 200 4 705 1 222 1 311 1 214 1 204 4 951 1 347 1 337 |
2 684 |
| BioSolutions 2 485 2 524 670 677 674 687 2 708 728 753 697 695 2 873 775 800 |
1 575 |
| BioMaterials 1 543 1 634 424 417 371 418 1 630 385 465 422 407 1 679 445 407 |
852 |
| Fine Chemicals 363 365 102 85 87 95 369 109 94 95 102 400 127 130 |
257 |
| Eliminations 0 - 1 - 1 0 - 1 0 - 2 0 -1 0 0 -1 0 0 |
0 |
| BioSolutions | |
| 1.1-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 |
1.1-30.6 |
| 2016 2017 2018 2018 2018 2018 2018 2019 2019 2019 2019 2019 2020 2020 |
2020 |
| Average gross sales price NOK per mtds 5 684 5 618 5 966 5 455 5 455 5 783 5 654 6 385 5 999 5 865 6 455 6 166 6 885 7 431 |
7 147 |
| Volume (`000 mtds) 444 450 107 122 122 117 468 115 125 119 111 470 115 106 |
221 |
| Specialities volume (`000 mtds) 80 83 86 86 |
|
| Contruction volume (`000 mtds) 214 210 212 209 |
|
| Industrial volume (`000 mtds) 150 157 170 175 |
|
| BioMaterials | |
| 1.1-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 1.7-30.9 1.10-31.12 1.1-31.12 1.1-31.3 1.4-30.6 |
1.1-30.6 |
| 2016 2017 2018 2018 2018 2018 2018 2019 2019 2019 2019 2019 2020 2020 |
2020 |
| Average gross sales price NOK per mt 9 992 10 589 10 129 10 202 10 532 10 528 10 337 10 724 10 561 10 982 10 417 10 665 11 382 12 579 |
11 931 |
| Volume (`000 mt) 152,3 150,7 40,0 39,1 33,3 37,7 150,1 34,5 42,4 37,6 38,6 153,1 40,0 33,9 |
73,9 |
| High specialised as % of total cellulose product sales volum 64 % 72 % 62 % 73 % |
|
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.